A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma. (2019)

• Record Type: Journal Article
• Authors: Masuhiro, Kentaro; Koh, Genju; Takata, So; Nasu, Shingo; Takada, Hiromune; Morita, Satomu; Tanaka, Ayako; Shiroyama, Takayuki; Morishita, Naoko; Suzuki, Hidekazu; Okamoto, Norio; Kawasumi, Hiromi; Konishi, Chihiro; Hirashima, Tomonori
• Is Part Of: Respiratory medicine case reports. Volume 28(2019)
• Publication Date: 2019
• Subjects: Lung cancer -- Follicular lymphoma -- Afatinib -- Synchronous -- Metachronous -- Double primary malignant tumors; EGFR-TKIs epidermal growth factor receptor-tyrosine kinase inhibitors -- ALK anaplastic lymphoma kinase -- LAD lung adenocarcinoma -- NSCLC non-small cell lung cancer -- R-CHOP cyclophosphamide, doxorubicin, vincristine, predonisone with rituximab -- CT computed tomography -- FL follicular lymphoma; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2019.100862
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR.